Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
186.13
+6.53 (3.64%)
At close: Sep 29, 2026, 4:00 PM EDT
188.66
+2.53 (1.36%)
After-hours: Sep 29, 2026, 7:59 PM EDT
Twist Bioscience Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Twist Bioscience stock has a consensus rating of "Buy" and an average price target of $109.58. The average 1-year stock price forecast is 41.13% lower than the current stock price, while the lowest is $36 (-80.66%) and the highest is $160 (-14.04%).
Price Target: $109.58 (-41.13%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Twist Bioscience stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 7 | 7 | 7 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 2 | 1 | 1 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Total | 10 | 10 | 11 | 11 | 11 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $160 → $190 | Buy | Maintains | $160 → $190 | +2.08% | Sep 29, 2026 |
| BWS Financial | BWS Financial | Sell Maintains $45 | Sell | Maintains | $45 | -75.82% | Sep 18, 2026 |
Unknown Analyst UBS No rating | UBS | Hold Initiates $144 | Hold | Initiates | $144 | -22.63% | Sep 9, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $115 | Buy | Reiterates | $115 | -38.22% | Aug 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $120 | Buy | Maintains | $120 | -35.53% | Aug 4, 2026 |
Financial Forecast
Revenue This Year
456.35M
from 376.57M
Increased by 21.19%
Revenue Next Year
540.36M
from 456.35M
Increased by 18.41%
EPS This Year
-0.60
from -2.12
EPS Next Year
-0.63
from -0.60
EPS and Forward PE are based on non-GAAP adjusted numbers.